Ben represents clients in a wide variety of complex civil and criminal litigation. In recent years, his practice has focused on intellectual property and licensing disputes, antitrust investigations, and False Claims Act allegations. His work primarily involves the pharmaceutical, biotechnology, telecommunications, and high tech industries. His clients include AstraZeneca, Google, MedImmune, Pfizer, and Sprint.
Ben has significant experience with all aspects of litigation from pre-trial investigations, through motions practice and discovery, to trials and appeals. He has represented corporations and individuals in a broad range of cases at both the trial and appellate levels and in both state and federal courts. He has tried cases before both judges and juries. He has also represented clients facing government investigations and has helped clients successfully mediate and settle disputes without resorting to formal litigation.
In 2018, Ben was awarded Pro Bono High Honors by the District of Columbia Courts and the D.C. Access to Justice Commission for his work representing indigent defendants. Ben is a member of the firm’s Sustainability Committee.
Born and raised in Wisconsin, Ben earned a B.A. magna cum laude from Harvard University in 2004. Before attending law school, he worked as a consultant for Lexecon, Inc., providing economic advice to law firms involved in complex litigation. In 2010, Ben earned a J.D. magna cum laude from New York University School of Law where he was a Pomeroy Scholar, an Allen Scholar, and a member of the Order of the Coif. While in law school, Ben was the Managing Editor of the New York University Law Review.
Ben joined the firm in 2011 after clerking for Chief Judge Dennis Jacobs of the United States Court of Appeals for the Second Circuit.
Ben now lives in Washington, D.C. with his wife and two daughters.
Though all cases vary and none is predictive, Ben’s experience includes:
- Defending a group of biotech companies against allegations of misappropriation of intellectual property, unfair competition, and tortious interference related to the development of a new pharmaceutical product
- Representing a major technology company in connection with a highly publicized FTC investigation into online search and search advertising
- Defending a nationwide telecommunications company in federal court against allegations of violating the False Claims Act
- Representing a pharmaceutical company in a two-week jury trial involving a contract dispute over the licensing of one of its key medical products
- Mediating a licensing dispute on behalf of a major pharmaceutical company against an academic institution
- Defending a journalist in a criminal bench trial against allegations that she trespassed and engaged in rioting while covering a major national news story
- Settling a shareholder dispute on behalf of the majority owner of a forestry company seeking to buyout the minority investors
- Representing an injured protester in a Section 1983 excessive force lawsuit against a local government and its police department
- Helping an international pharmaceutical company evaluate its licenses and patent rights in anticipation of the launch of a new pharmaceutical product
- Arguing an appeal before the North Dakota Supreme Court on behalf of a protester who was convicted of trespassing and rioting